A study published in JAMA reports on data showing that Combination ICS-SABA and ICS-Formoterol asthma treatments are more ...

This study highlights the benefits of anti-inflammatory inhalers in asthma management, showing reduced complications and ...

The BATURA trial ended early due to high efficacy data at pre-planned analysis. Topline results were announced from a phase 3b trial evaluating albuterol/budesonide metered dose inhaler in ...

Objectives Continuous albuterol nebulization is generally administered at 2.5–20 mg/hr at most centers. We examined the effect of high-dose (75 or 150 mg/hr) albuterol on clinical variables in ...

Early fall is when asthma flare-ups peak in the US ... GSK’s metered-dose Ventolin inhaler, prescribed to around 35 million people globally, accounts for 49% of the company’s entire carbon ...

Increment in HR vs initial % 12.6 ± 10.8 Increment in HR from hospital discharge, % 87.9 ± 32.1 Decrement in DBP vs initial, % 43.9 ± 15.2 Decrement in DBP vs hospital discharge, % 53.5 ± 12.0 ...

The inhaler cleared the FDA’s desk in January 2023 as the first and only rescue medication for as-needed use to curb the risk of asthma exacerbations in adults. Unlike traditional albuterol ...

UK-based pharmaceutical company AstraZeneca has reported that its Phase IIIb BATURA trial of Airsupra (albuterol/budesonide) in patients with intermittent or mild persistent asthma met its primary ...